A Phase 1, Open-Label, Drug-Drug Interaction Study Designed to Evaluate the Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-gp Substrate Dabigatran Etexilate in Healthy Subjects
Kunta et al. • 2024 • AAPS 2024 Congress
Kunta et al. • 2024 • AAPS 2024 Congress
Hunt et al. • 2017 • Clin Pharmacol Drug Dev. 2017 Oct 2. doi: 10.1002/cpdd.389.
Bali et al. • 2016 • J Clin Endocrinol Metab. 2016;101(11):4305-4312.
Atucha et al. • 2015 • Endocrinology. 2015;156(11):4105-4114.
Hunt et al. • 2017 • J Med Chem. 2017;60(8):3405-3421.
Clark et al. • 2008 • Bioorg Med Chem Lett. 2008;18(4):1312-7.
Butts KA, Phillips AG. • 2013 • Int J Neuropsychopharmacol. 2013;16(8):1799-807.
Nguyen et al. • 2017 • Physiol Behav. 2017;178:82-92.
Solomon et al. • 2014 • Horm Behav. 2014;65(4):363-71.
Zalachoras et al. • 2013 • Proc Natl Acad Sci U S A. 2013;110(19):7910-7915.
© 2024 Corcept Therapeutics, Incorporated